The MEDTEX Summit featured a historic delegation of six tier-one international venture capital firms—Novo Holdings, Insight Partners, Illumina Ventures, aMoon Fund, Playground Global, and Ascenta Capital—collectively managing over NT$8 trillion in assets.

Investment Frontiers & Portfolios:

• AI-Driven Drug Discovery: The forum highlighted startups like Manifold Bio (protein engineering), Arrepath (anti-infective targets), and Iambic (AI-accelerated lead discovery).
• Next-Gen Modalities: Focus areas included Molecular Glues (Coltac Therapeutics), mRNA therapeutics (Strand Therapeutics), and orally bioavailable cyclic peptides (Insamo).
• Taiwanese Leaders: Local firms gaining international traction include:
• Syncell: Spatial proteomics for target identification.
• ImmunAdd: Saponin-based vaccine adjuvant platforms.
• StemCyte (永笙生技): Its umbilical cord blood product, REGENECYTE, has secured U.S. FDA BLA approval—the only allogeneic cell therapy from Taiwan to hold a U.S. license. With over 2,300 clinical transplants and 36,000 units in its public bank, StemCyte is positioned as a premier global CDMO partner for cell-based therapies.

Resource: 六大國際創投親赴台灣 MEDTEX建構全球生醫投資新窗口